Literature DB >> 9013991

Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved.

C Mathieu1, K Casteels, R Bouillon, M Waer.   

Abstract

After bone marrow transplantation, complete nonobese diabetic (NOD) into (NOD x C57Bl/10)F1 chimeras developed insulitis in 100% (7/7) and diabetes in 58% (7/12) of cases. In contrast, when mixed chimerism was induced, a near complete protection against insulitis (3/23, p < 0.0001 vs complete chimeras) and diabetes (0/25, p < 0.001 vs complete chimeras) was achieved even in chimeras with as few as 5% F1 cells. In cotransfer experiments, splenocytes from mixed chimeras failed to prevent diabetes, thus overruling a role for suppressor cells in protection. Whereas splenocytes from complete chimeras transferred diabetes into young irradiated NOD mice in all cases, NOD splenocytes from mixed chimeras only rarely transferred diabetes (3/16, p < 0.01 vs complete chimeras), suggesting that the latter cells had developed tolerance toward beta cells. To achieve this tolerance, the presence of an F1 thymus was not needed. Indeed, whereas splenocytes isolated from complete chimeras were diabetogenic when transferred into neonatally thymectomized irradiated NOD recipients (3/4), they failed to induce diabetes when transferred into neonatally thymectomized irradiated F1 recipients in case again a state of mixed chimerism was induced (0/4, p < 0.001 vs NOD recipients). Finally, a role for non-MHC Ags was demonstrated by experiments in F1 mice crossed between NOD and C57Bl/6, a strain congenic to C57Bl/10. Here protection against disease was only seen in the presence of high levels of F1 cells (>25%). In conclusion, mixed bone marrow chimerism can induce self-tolerance in autoimmunity prone NOD immune cells. This can be achieved extrathymically but may depend on non-MHC Ags and the level of chimerism.

Entities:  

Mesh:

Year:  1997        PMID: 9013991

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Bone marrow transplantation in the treatment of systemic sclerosis.

Authors:  F Viganego; R Nash; D E Furst
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

3.  Genetic differences in bone marrow-derived lymphoid lineages control susceptibility to experimental autoimmune myocarditis.

Authors:  Haiyan S Li; Davinna L Ligons; Noel R Rose; Mehmet L Guler
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

Review 4.  The contribution of hematopoietic stem cells to beta-cell replacement.

Authors:  Valeria Sordi; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2009-04       Impact factor: 4.810

5.  Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice.

Authors:  Boris Nikolic; Takashi Onoe; Yasuo Takeuchi; Zain Khalpey; Valeria Primo; Igor Leykin; R Neal Smith; Megan Sykes
Journal:  Transplantation       Date:  2010-01-15       Impact factor: 4.939

Review 6.  Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus.

Authors:  Nick Giannoukakis; Massimo Trucco
Journal:  Rev Endocr Metab Disord       Date:  2003-12       Impact factor: 9.306

7.  Immunological Basis for Rapid Progression of Diabetes in Older NOD Mouse Recipients Post BM-HSC Transplantation.

Authors:  Nan Wang; Narendiran Rajasekaran; Tieying Hou; Claudia Macaubas; Elizabeth D Mellins
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

Review 8.  Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases.

Authors:  Jean-François Bach
Journal:  Arthritis Res       Date:  2002-05-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.